James A. Goodman1, Gary B. Freeman2, William Angus2, Thomas P. Brown3, Peter Cheng-te Chou1, Kelly R. Bales4
1Pharmatherapeutics Precision Medicine Preclinical Imaging, Pfizer Worldwide Research and Development, Groton, CT, United States; 2General Toxicology, Pfizer Worldwide Research and Development, Groton, CT, United States; 3Investigative Pathology, Pfizer Worldwide Research and Development, Groton, CT, United States; 4Neuroscience Research Unit, Pfizer Worldwide Research and Development, Groton, CT, United States
Amyloid Related Imaging Abnormalities of the microhemorrhage (ARIA-H) and effusive/edematous (ARIA-E) types have been reported in clinical trials in AD patients given agents targeting -amyloid, prompting interest in identifying animal models to elucidate these ARIAs. While ARIA-H has been reported in transgenic mouse models, no publications to our knowledge describe ARIA-E in mice. We imaged 3 lines of aged transgenic mice: APP+PS1, Tg2576, and HCHWA-Dutch. While most APP+PS1 mice had T2* hypointensities representing ARIA-H and T2 hyperintensities representing ARIA-E, Tg2576 and HCHWA-Dutch mice had neither, suggesting that the APP+PS1 line is a viable model for evaluating the pathogenesis of ARIA.